Karoksazon
Jump to navigation
Jump to search
 |
|||
| (IUPAC) ime | |||
|---|---|---|---|
| 2-(2-okso-4H-1,3-benzoksazin-3-il)acetamid | |||
| Klinički podaci | |||
| Identifikatori | |||
| CAS broj | 18464-39-6 | ||
| ATC kod | nije dodeljen | ||
| PubChem[1][2] | 29083 | ||
| ChemSpider[3] | 27057 | ||
| UNII | 807N226MNL  |
||
| Hemijski podaci | |||
| Formula | C10H10N2O3 | ||
| Mol. masa | 206,20 g/mol | ||
| SMILES | eMolekuli & PubHem | ||
|
|||
| Farmakoinformacioni podaci | |||
| Trudnoća | ? | ||
| Pravni status | ℞ Prescription only | ||
| Način primene | Oralno | ||
Karoksazon (Surodil, Timostenil) je antidepresiv koji se nekad koristio za tretman depresije ali više nije u prodaji.[4][5] On deluje kao reverzibilni inhibitor monoaminske oksidaze (MAOI) oba podtipa: MAO-A i MAO-B, sa pet puta većom potentnošću na MAO-B.[6][7][8][9][10]
Sadržaj/Садржај
Reference[uredi - уреди | uredi izvor]
- ↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). "PubChem as a public resource for drug discovery.". Drug Discov Today 15 (23-24): 1052–7. PMID 20970519. doi:10.1016/j.drudis.2010.10.003.
- ↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). "Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities". Annual Reports in Computational Chemistry 4: 217–241. doi:10.1016/S1574-1400(08)00012-1.
- ↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). "Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining". J Cheminform 2 (1): 3. PMID 20331846. doi:10.1186/1758-2946-2-3.
- ↑ Dictionary of organic compounds. London: Chapman & Hall. 1996. ISBN 0-412-54090-8. http://books.google.com/books?id=zNZfxR-CsYcC&lpg=PA1254&dq=caroxazone&as_brr=3&pg=PA1254#v=onepage&q=&f=false.
- ↑ Cecchini S, Petri P, Ardito R, Bareggi SR, Torriti A (1978). "A comparative double-blind trial of the new antidepressant caroxazone and amitriptyline". The Journal of International Medical Research 6 (5): 388–94. PMID 359383.
- ↑ Lieberman, A. N. (1994). Monoamine oxidase inhibitors in neurological diseases. New York: M. Dekker. ISBN 0-8247-9082-0. http://books.google.com/books?id=kJP3f9YKSrUC&lpg=PA56&ots=XKfRcAphTU&dq=caroxazone%20%22MAO-A%22&pg=PA56#v=onepage&q=&f=false.
- ↑ Moretti A, Caccia C, Martini A et al. (May 1981). "Effect of caroxazone, a new antidepressant drug, on monoamine oxidases in healthy volunteers". British Journal of Clinical Pharmacology 11 (5): 511–5. PMC 1401585. PMID 7272163.
- ↑ Moretti A, Caccia C, Calderini G, Menozzi M, Amico A (October 1981). "Studies on the mechanism of action of caroxazone, a new antidepressant drug". Biochemical Pharmacology 30 (19): 2728–31. PMID 6170295. doi:10.1016/0006-2952(81)90549-9.
- ↑ Martini A, Bonollo L, Nicolis FB, Sega R, Palermo A (June 1981). "Effects of caroxazone, a reversible monoamine oxidase inhibitor, on the pressor response to oral tyramine in man". British Journal of Clinical Pharmacology 11 (6): 611–5. PMC 1402186. PMID 7272178.
- ↑ Martini A, Bonollo L, Nicolis FB, Sega R, Palermo A, Braibanti E (June 1981). "Effects of caroxazone, a reversible monoamine oxidase inhibitor, on the pressor response to intravenous tyramine in man". British Journal of Clinical Pharmacology 11 (6): 605–10. PMC 1402193. PMID 7272177.
Literatura[uredi - уреди | uredi izvor]
- Lieberman, A. N. (1994). Monoamine oxidase inhibitors in neurological diseases. New York: M. Dekker. ISBN 0-8247-9082-0. http://books.google.com/books?id=kJP3f9YKSrUC&lpg=PA56&ots=XKfRcAphTU&dq=caroxazone%20%22MAO-A%22&pg=PA56#v=onepage&q=&f=false.
- Dictionary of organic compounds. London: Chapman & Hall. 1996. ISBN 0-412-54090-8. http://books.google.com/books?id=zNZfxR-CsYcC&lpg=PA1254&dq=caroxazone&as_brr=3&pg=PA1254#v=onepage&q=&f=false.
Vidi još[uredi - уреди | uredi izvor]
Spoljašnje veze[uredi - уреди | uredi izvor]
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
